Optimization of Minocycline for Helicobacter Pylori Rescue Treatment
Key facts
- Who runs it
- Shanghai Jiao Tong University School of Medicine
- Where
- China4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 480 people enrolled
- Started
- 21 Aug 2024
- Ended
- 21 Feb 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vonoprazan
- Bismuth Potassium Citrate
- Tetracycline,Metronidazole
- Minocycline,Metronidazole
- Record updated
- 25 March 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Ability and willingness to participate in the study and to sign and give informed consent
- Confirmed H. pylori infection and with previous treatment experience
Who cannot take part
- Previous history of tuberculosis
- administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks
- history of gastrectomy
- Allergy to any of the study drugs
- severe systemic diseases or malignancy
- under 18 or over 80 years old
- subjects naive to H. pylori treatment,
- pregnant or lactating women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The efficacy of bismuth-containing quadruple therapy with minocycline and metronidazole was not inferior to classical bismuth quadruple therapy for refractory H. pylori infection, though also accompanied with high occurrence of adverse events (55.4%). Optimization of minocycline-based regimen to achieve high eradication rate with fewer adverse events is imperative. This study aimed to compare the efficacy and tolerability of a 14-day bismuth-containing quadruple rescue therapy with different dosage of minocycline and metronidazole compared to classical bismuth quadruple therapy.
The 4 groups in the trial
- Minocycline group ATreatment being tested
Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg tid, Metronidazole 400mg tid
Treatment: Vonoprazan, Bismuth Potassium Citrate, and Minocycline,Metronidazole
- Minocycline group BTreatment being tested
Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg bid, Metronidazole 400mg qid
Treatment: Vonoprazan, Bismuth Potassium Citrate, and Minocycline,Metronidazole
- Minocycline group CTreatment being tested
Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg bid, Metronidazole 400mg tid
Treatment: Vonoprazan, Bismuth Potassium Citrate, and Minocycline,Metronidazole
- Tetracycline groupExisting treatment, for comparison
Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Tetracycline 500mg qid, Metronidazole 400mg qid
Treatment: Vonoprazan, Bismuth Potassium Citrate, and Tetracycline,Metronidazole
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optimization of Minocycline-containing Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: a Multicentre, Randomized Controlled Trial
- Publications
- Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Randomized Controlled Trial.Journal of gastroenterology and hepatology, 2026
- Record updated
- 25 March 2026